Brookstone Capital Management Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

Brookstone Capital Management decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,953 shares of the company’s stock after selling 1,469 shares during the quarter. Brookstone Capital Management’s holdings in Johnson & Johnson were worth $9,070,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. GW&K Investment Management LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $35,000. Dark Forest Capital Management LP raised its position in Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after acquiring an additional 188 shares in the last quarter. Atlantic Private Wealth LLC acquired a new position in Johnson & Johnson in the first quarter valued at approximately $32,000. Ruedi Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $42,000. Finally, Kepos Capital LP purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $45,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, insider William Hait sold 14,698 shares of the stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Up 0.6 %

Shares of JNJ stock opened at $162.41 on Tuesday. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The firm has a market cap of $422.10 billion, a PE ratio of 32.88, a price-to-earnings-growth ratio of 3.26 and a beta of 0.54. The company has a 50-day moving average of $166.21 and a two-hundred day moving average of $161.83. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. During the same quarter last year, the company posted $2.59 EPS. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.03 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.

Wall Street Analyst Weigh In

Several research firms recently commented on JNJ. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Citigroup initiated coverage on Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective on the stock. Wells Fargo & Company decreased their target price on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research report on Thursday, August 31st. Finally, Raymond James dropped their target price on shares of Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 5th. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $170.65.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.